Analyst Price Target

Business

Cocoa Price Retreat Offers Breather for Mondelez, Morgan Stanley Sees Clearer Path to Earnings Growth

As cocoa futures pull back from historic highs, Morgan Stanley boosts its price target for snack giant Mondelez International, citing improved earnings visibility. The firm maintains an Overweight rating, highlighting the company's resilient financials and shareholder returns amidst lingering sales growth uncertainties.

Jan 30, 2026

Business

Global Sugar Glut Deepens, Sending Prices to Multi-Year Lows

Sugar futures tumbled further this week, with New York prices hitting a 2.5-month low and London white sugar sinking to a five-year trough, as analysts warn of swelling global surpluses driven by record harvests in Brazil and India.

Jan 30, 2026

Business

Gas Prices Climb for Second Straight Week in Lower Atlantic States

Drivers across the Southeast are feeling the pinch as average pump prices in the Lower Atlantic region rose to $2.75 per gallon this week, continuing an upward trend that analysts link to seasonal demand and refinery adjustments.

Jan 30, 2026

Business

Beyond the Chatbot: Veteran Analyst Pivots AI Investment Thesis to Physical World, Backs Tesla and Nvidia

As Wall Street remains fixated on software-based AI, a leading tech analyst argues the next trillion-dollar opportunity lies in 'physical AI'—machines that see, move, and act. Dan Ives of Wedbush singles out Tesla and Nvidia as the indispensable architects of this new industrial revolution.

Feb 2, 2026

Business

Super Bowl Ad Prices Soar to Record $10 Million, Testing the Limits of Marketing Budgets

As the Super Bowl approaches, the cost of a 30-second commercial spot has reached an unprecedented $10 million, driven by intense demand and bundled packages with the Olympics. Major brands are betting big with celebrity-studded campaigns, but analysts question the long-term value of such staggering investments.

Feb 2, 2026

Business

Palantir's AI Ambitions Fuel Analyst Optimism: Is It a Top Stock Pick for 2026?

As Palantir Technologies (PLTR) prepares to report Q4 2025 results, a wave of bullish analyst upgrades points to surging commercial demand for its AI platform, driving a debate over its valuation and long-term potential.

Feb 2, 2026

Business

Analysts Boost PLS Group Outlook, Forecasting 109% Revenue Surge by 2026

PLS Group (ASX:PLS) receives significant forecast upgrades from analysts, with revenue projections for 2026 raised to AU$1.6b and the company expected to return to profitability this year.

Feb 2, 2026

Business

Markets Edge Higher Amid Earnings Anticipation; Oil Prices Slide on Geopolitical, Demand Concerns

U.S. stocks advanced cautiously Monday as investors braced for a wave of corporate earnings reports, while crude oil prices tumbled sharply. The focus remains on key tech results and evolving geopolitical developments affecting global trade and energy markets.

Feb 2, 2026

Business

NorthWestern Energy's Valuation Under Scrutiny Ahead of Earnings

As NorthWestern Energy Group (NWE) approaches its quarterly report, a surge in share price has investors questioning whether optimism has outpaced fundamentals. With shares trading above analyst targets, the debate centers on future growth prospects versus current valuation concerns.

Feb 2, 2026

Business

Tesla's Fork in the Road: AI Ambitions Clash with Auto Woes, Splitting Wall Street Between $500 and $350 Targets

Tesla's strategic pivot from electric vehicles to AI and robotics, coupled with declining automotive revenue, has created a stark divide among analysts. Bullish forecasts see shares hitting $500, while bears warn of a drop to $350, leaving investors to weigh Elon Musk's high-stakes vision against core business challenges.

Feb 2, 2026

Business

Zoom's Strategic Bet on Anthropic Fuels Analyst Optimism for an AI-Driven Revival

Zoom Video Communications, bolstered by stable post-pandemic cash flows, is drawing renewed Wall Street attention following its venture investment in AI leader Anthropic, with some analysts touting it as a compelling AI play.

Feb 2, 2026

Business

Nvidia's Massive Bet on CoreWeave: Analysts Weigh AI Cloud Giant's Prospects Ahead of Earnings

As CoreWeave prepares to report Q4 earnings, the market's focus sharpens on the AI infrastructure firm that has become Nvidia's largest disclosed investment. With a soaring stock and a bold expansion plan, analysts are revisiting the thesis amid both optimism and legal headwinds.

Feb 2, 2026

Business

Las Vegas Sands Stock: Analysts See Value Despite Macau Headwinds and Market Underperformance

While Las Vegas Sands shares have struggled to keep pace with the broader market, a majority of Wall Street analysts maintain a constructive outlook, betting on a recovery in Macau and the company's long-term integrated resort model.

Feb 2, 2026

Business

Analysts Maintain Cautious Optimism for Colgate-Palmolive Despite Market Underperformance

While Colgate-Palmolive's stock has trailed the S&P 500 over the past year, Wall Street analysts see a resilient business model and strong international presence supporting long-term growth, maintaining a 'Moderate Buy' consensus.

Feb 2, 2026

Business

Dell's AI Bet Faces Market Skepticism: Can Analysts' Optimism Overcome Slumping Shares?

Despite Dell Technologies' strategic push into AI infrastructure and analyst endorsements, its stock continues to underperform the broader market, raising questions about the timing of its promised turnaround.

Feb 2, 2026

Business

Goodyear Poised for Growth as Replacement Tire Market Gains Momentum

Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.

Feb 2, 2026

Business

Mobileye Eyes 2026 as Pivotal Year Amid Analyst Backing and Strategic Shifts

Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.

Feb 2, 2026

Business

Analysts See Long-Term Promise in Legend Biotech's Carvykti Despite Fourth-Quarter Sales Shortfall

While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.

Feb 2, 2026

Business

Jefferies Downgrades Amicus to 'Buy' Amid BioMarin Acquisition, Sees Limited Upside

Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.

Feb 2, 2026

Business

Target's Leadership Shuffle: New CEO and Board Members Signal Renewed Focus on Store Revamp

Amidst sluggish sales and intense competition, Target appoints Michael Fiddelke as CEO and refreshes its board, placing store revitalization and operational efficiency at the heart of its turnaround strategy.

Feb 2, 2026